Zymeworks Operating Income 2016-2021 | ZYME

Zymeworks operating income from 2016 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Zymeworks Annual Operating Income
(Millions of US $)
2020 $-187
2019 $-151
2018 $-33
2017 $-9
2016 $-38
2015 $-20
Zymeworks Quarterly Operating Income
(Millions of US $)
2021-06-30 $-69
2021-03-31 $-45
2020-12-31 $-38
2020-09-30 $-74
2020-06-30 $-40
2020-03-31 $-36
2019-12-31 $-74
2019-09-30 $-34
2019-06-30 $-29
2019-03-31 $-15
2018-12-31 $8
2018-09-30 $-20
2018-06-30 $-2
2018-03-31 $-20
2017-12-31 $33
2017-09-30 $-17
2017-06-30 $-9
2017-03-31 $-16
2016-12-31 $-11
2016-09-30 $-11
2016-06-30 $-7
2016-03-31 $-10
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.323B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29